Clinical Trial Update: A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, reactogenicity, and immune response of a targeted immunotherapy against herpes simplex virus in healthy Japanese adults aged 18…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Simplex Infection

Drugs mentioned

• HSV-targeted immunotherapy

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Simplex | Phase 1 | Status: COMPLETED | Results posted: 2025-06-12